新股首日 | 华健未来-B(06132)首挂上市早盘平开公司拥有三个核心产品但尚未获批销售

智通财经06-23

智通财经APP获悉，华健未来-B(06132)首挂上市，公告显示，每股定价81.8港元，共发行1360万股股份，每手100股，所得款项净额约10.19亿港元。截至发稿，无涨跌，报81.8港元，成交额3.89亿港元。招股书显示，华健未来为一家于2017年由致力研发自身免疫、代谢及肿瘤学疾病疗法的行业专家团队创立的临床阶段生物科技公司。公司拥有三个核心产品HJ787、HJ178及HJ891，均为自行...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2645790009?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-23 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645790009","market":"hk","top_or_hot":-1,"title":"新股首日 | 华健未来-B(06132)首挂上市 早盘平开 公司拥有三个核心产品但尚未获批销售","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，华健未来-B(06132)首挂上市，公告显示，每股定价81.8港元，共发行1360万股股份，每手100股，所得款项净额约10.19亿港元。截至发稿，无涨跌，报81.8港元，成交额3.89亿港元。招股书显示，华健未来为一家于2017年由致力研发自身免疫、代谢及肿瘤学疾病疗法的行业专家团队创立的临床阶段生物科技公司。公司拥有三个核心产品HJ787、HJ178及HJ891，均为自行...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457306.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股首日 | 华健未来-B(06132)首挂上市 早盘平开 公司拥有三个核心产品但尚未获批销售</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股首日 | 华健未来-B(06132)首挂上市 早盘平开 公司拥有三个核心产品但尚未获批销售\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-23 09:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1457306.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，华健未来-B(06132)首挂上市，公告显示，每股定价81.8港元，共发行1360万股股份，每手100股，所得款项净额约10.19亿港元。截至发稿，无涨跌，报81.8港元，成交额3.89亿港元。招股书显示，华健未来为一家于2017年由致力研发自身免疫、代谢及肿瘤学疾病疗法的行业专家团队创立的临床阶段生物科技公司。公司拥有三个核心产品HJ787、HJ178及HJ891，均为自行...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457306.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1457306.html","article_id":"2645790009","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645790009","pubTimestamp":1782177810,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，华健未来-B首挂上市，公告显示，每股定价81.8港元，共发行1360万股股份，每手100股，所得款项净额约10.19亿港元。招股书显示，华健未来为一家于2017年由致力研发自身免疫、代谢及肿瘤学疾病疗法的行业专家团队创立的临床阶段生物科技公司。迄今，公司并无产品获批准进行商业销售，亦无自产品销售产生任何收益。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IPOS":"Renaissance International IPO ETF","06132":"华健未来-B"},"translate_title":"First day of new shares | Huajian Future-B (06132) first listed in early trading. The company has three core products but has not been approved for sale","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06132":1.5,"IPOS":1.5},"content_text":"智通财经APP获悉，华健未来-B(06132)首挂上市，公告显示，每股定价81.8港元，共发行1360万股股份，每手100股，所得款项净额约10.19亿港元。截至发稿，无涨跌，报81.8港元，成交额3.89亿港元。招股书显示，华健未来为一家于2017年由致力研发自身免疫、代谢及肿瘤学疾病疗法的行业专家团队创立的临床阶段生物科技公司。公司拥有三个核心产品HJ787、HJ178及HJ891，均为自行开发、小分子、国家药监局1类1类创新药。迄今，公司并无产品获批准进行商业销售，亦无自产品销售产生任何收益。华健未来已为小分子药物建立开发平台，涵盖从药物设计、高效合成、筛选与评估、药理研究及全面的CMC研究到临床策略与运作以及转化医学的全流程。在该平台上，公司将计算机模拟与实验药物设计和筛选、靶向和快速类药性评估以及高效的CMC开发和临床研究结合起来。使用该一体化方法，公司已推进在各治疗领域具有显著差异的多种候选药物。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645790009","isCrawlerRequest":true}

新股首日 | 华健未来-B(06132)首挂上市 早盘平开 公司拥有三个核心产品但尚未获批销售

精彩评论

新股首日 | 华健未来-B(06132)首挂上市早盘平开公司拥有三个核心产品但尚未获批销售